After years of lagging behind the broader equity market, the healthcare sector is looking for a turnaround in 2026. While macroeconomic uncertainty persists, investors focused on fundamental strength may find opportunities beneath the surface. Some industry leaders are voluntarily taking short-term hits to position themselves for sustainable long-term growth. CVS Health (CVS) and Vertex Pharmaceuticals (VRTX) stand out as prime examples.
CVS Health staged an impressive comeback in 2025, with shares surging more than 70% on improved financial results. Rather than resting on its laurels, the company is rolling out even bolder restructuring initiatives this year. CVS plans to significantly scale back its Medicare Advantage business—a segment long plagued by cost control issues and compressed margins. Meanwhile, its insurance arm Aetna will exit the Obamacare marketplace entirely. These moves mean sacrificing substantial near-term revenue in favor of long-term profitability.
“These decisions clearly signal that management is no longer chasing top-line expansion for its own sake,” noted one market analyst. “Instead, they’re committed to building a higher-margin, more sustainable business model.”
While these contractions may not dramatically impact CVS’s 2026 financial statements, they lay a healthier foundation for the company’s vast healthcare ecosystem—encompassing nationwide retail locations, pharmacy benefit management operations, and deep customer relationships. For investors willing to hold for three years or more, the current share price pullback could represent an attractive entry point.
Vertex Pharmaceuticals takes a different path to long-term value creation, focusing on patient cultivation of its pipeline. As the dominant force in cystic fibrosis treatment, Vertex has relied almost exclusively on this rare disease franchise to fuel growth for years. But 2026 could mark a pivotal transition from “single-product giant” to diversified specialty pharma.
Journavx for acute pain and Casgevy for sickle cell disease, both launched last year, are steadily ramping up. The company expects these two new products to generate at least $500 million in revenue this year—modest compared to 2025’s $12 billion total, but their growth trajectory hints at future potential.
More compelling are the clinical catalysts on the horizon. Vertex plans to file for approval of zimislecel, an investigational therapy for Type 1 diabetes, later this year. Additionally, phase 3 data readouts are expected for next-generation programs including povetacicept in IgA nephropathy and inaxaplin in APOL-1 mediated kidney disease. Successful milestones here would fundamentally reshape market perception of Vertex beyond its CF franchise.
“Even if the core business eventually faces competition, these new assets provide ample cushion,” commented a biotech analyst. Trading near-term income statement fireworks for steady pipeline progress—this is long-term thinking in action.
Healthcare investing often demands patience that runs counter to human nature. Through portfolio reshaping and pipeline cultivation, CVS Health and Vertex Pharmaceuticals demonstrate strategic discipline—sacrificing today for tomorrow. In a market obsessed with quarterly results, these two giants remind us that for investors willing to look beyond the horizon, patience isn’t just a virtue. It’s a strategy.
